Literature DB >> 20550572

Alpha-synuclein mediates alterations in membrane conductance: a potential role for alpha-synuclein oligomers in cell vulnerability.

Li Rebekah Feng1, Howard J Federoff, Stefano Vicini, Kathleen A Maguire-Zeiss.   

Abstract

alpha-Synuclein has been linked to the pathogenesis of Parkinson's disease and other synucleinopathies through its propensity to form toxic oligomers. The exact mechanism for oligomeric synuclein-directed cell vulnerability has not been fully elucidated, but one hypothesis portends the formation of synuclein-containing pores within cell membranes leading to leak channel-mediated calcium influx and subsequent cell death. Here we demonstrate synuclein-induced formation of sodium dodecyl sulfate-stable oligomers, intracellular synuclein-positive aggregates, alterations in membrane conductance reminiscent of leak channels and subsequent cytotoxicity in a dopaminergic-like cell line. Furthermore we demonstrate that the synuclein-induced membrane conductance changes are blocked by direct extracellular application of an anti-synuclein antibody. The work presented here confirms that synuclein overexpression leads to membrane conductance changes and demonstrates for the first time through antibody-blocking studies that synuclein plays a direct role in the formation of leak channels.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20550572      PMCID: PMC2900531          DOI: 10.1111/j.1460-9568.2010.07266.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  69 in total

1.  Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system.

Authors:  A Abeliovich; Y Schmitz; I Fariñas; D Choi-Lundberg; W H Ho; P E Castillo; N Shinsky; J M Verdugo; M Armanini; A Ryan; M Hynes; H Phillips; D Sulzer; A Rosenthal
Journal:  Neuron       Date:  2000-01       Impact factor: 17.173

2.  Mitochondrial translocation of alpha-synuclein is promoted by intracellular acidification.

Authors:  Nelson B Cole; Diane Dieuliis; Paul Leo; Drake C Mitchell; Robert L Nussbaum
Journal:  Exp Cell Res       Date:  2008-03-28       Impact factor: 3.905

3.  Differentiated dopaminergic MN9D cells only partially recapitulate the electrophysiological properties of midbrain dopaminergic neurons.

Authors:  C E Rick; A Ebert; T Virag; M C Bohn; D J Surmeier
Journal:  Dev Neurosci       Date:  2006       Impact factor: 2.984

4.  Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine.

Authors:  Eunsung Junn; M Maral Mouradian
Journal:  Neurosci Lett       Date:  2002-03-08       Impact factor: 3.046

5.  Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.

Authors:  K A Conway; J C Rochet; R M Bieganski; P T Lansbury
Journal:  Science       Date:  2001-11-09       Impact factor: 47.728

Review 6.  Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.

Authors:  Michael J Volles; Peter T Lansbury
Journal:  Biochemistry       Date:  2003-07-08       Impact factor: 3.162

Review 7.  Alpha-synuclein and Parkinson's disease: a proteomic view.

Authors:  Mauro Fasano; Leonardo Lopiano
Journal:  Expert Rev Proteomics       Date:  2008-04       Impact factor: 3.940

8.  Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.

Authors:  Hilal A Lashuel; Benjamin M Petre; Joseph Wall; Martha Simon; Richard J Nowak; Thomas Walz; Peter T Lansbury
Journal:  J Mol Biol       Date:  2002-10-04       Impact factor: 5.469

9.  Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain.

Authors:  Latha Devi; Vijayendran Raghavendran; Badanavalu M Prabhu; Narayan G Avadhani; Hindupur K Anandatheerthavarada
Journal:  J Biol Chem       Date:  2008-02-01       Impact factor: 5.157

Review 10.  Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease.

Authors:  Jean-Christophe Rochet; Tiago Fleming Outeiro; Kelly A Conway; Tomas T Ding; Michael J Volles; Hilal A Lashuel; Robert M Bieganski; Susan L Lindquist; Peter T Lansbury
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 2.866

View more
  34 in total

Review 1.  Misfolded α-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease.

Authors:  Dawn Béraud; Kathleen A Maguire-Zeiss
Journal:  Parkinsonism Relat Disord       Date:  2012-01       Impact factor: 4.891

Review 2.  Drug targets from genetics: α-synuclein.

Authors:  Karin M Danzer; Pamela J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

3.  α-Synuclein oligomers pump it up!

Authors:  Philipp J Kahle; Naoto Sugeno; Angelos Skodras
Journal:  EMBO J       Date:  2015-09-15       Impact factor: 11.598

4.  Autonomic dysfunction and plasticity in micturition reflexes in human α-synuclein mice.

Authors:  Robert W Hamill; John D Tompkins; Beatrice M Girard; Richard T Kershen; Rodney L Parsons; Margaret A Vizzard
Journal:  Dev Neurobiol       Date:  2012-06       Impact factor: 3.964

5.  Dopamine and paraquat enhance α-synuclein-induced alterations in membrane conductance.

Authors:  Li Rebekah Feng; Kathleen A Maguire-Zeiss
Journal:  Neurotox Res       Date:  2011-07-07       Impact factor: 3.911

6.  Number and Brightness analysis of alpha-synuclein oligomerization and the associated mitochondrial morphology alterations in live cells.

Authors:  N Plotegher; E Gratton; L Bubacco
Journal:  Biochim Biophys Acta       Date:  2014-02-20

7.  Nanodelivery of Cerebrolysin and Rearing in Enriched Environment Induce Neuroprotective Effects in a Preclinical Rat Model of Parkinson's Disease.

Authors:  C Requejo; J A Ruiz-Ortega; H Cepeda; A Sharma; H S Sharma; A Ozkizilcik; R Tian; H Moessler; L Ugedo; J V Lafuente
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

8.  Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders.

Authors:  Stefano G Daniele; Dawn Béraud; Connor Davenport; Kui Cheng; Hang Yin; Kathleen A Maguire-Zeiss
Journal:  Sci Signal       Date:  2015-05-12       Impact factor: 8.192

9.  A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.

Authors:  T T Myöhänen; M J Hannula; R Van Elzen; M Gerard; P Van Der Veken; J A García-Horsman; V Baekelandt; P T Männistö; A M Lambeir
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

10.  The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.

Authors:  Mari H Savolainen; Christopher T Richie; Brandon K Harvey; Pekka T Männistö; Kathleen A Maguire-Zeiss; Timo T Myöhänen
Journal:  Neurobiol Dis       Date:  2014-04-16       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.